X4 Pharmaceuticals gets positive FDA input on 4WARD Phase 3 trial
FDA agreed to a reduced sample size for X4 Pharmaceuticals’ Global 4WARD Phase 3 chronic neutropenia trial. Enrollment is expected to complete by year-end 2026, with topline data due in H1 2028.